Martin Zamora
Concepts (287)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Transplantation | 32 | 2023 | 338 | 5.110 |
Why?
| | Cytomegalovirus Infections | 7 | 2012 | 206 | 1.630 |
Why?
| | Antiviral Agents | 12 | 2023 | 767 | 1.350 |
Why?
| | Respiratory Syncytial Virus Infections | 4 | 2023 | 136 | 1.210 |
Why?
| | Lung Diseases | 7 | 2017 | 787 | 1.030 |
Why?
| | Bronchiolitis Obliterans | 7 | 2015 | 66 | 0.750 |
Why?
| | Ganciclovir | 5 | 2012 | 53 | 0.730 |
Why?
| | Respiratory Syncytial Virus, Human | 2 | 2023 | 81 | 0.720 |
Why?
| | Postoperative Complications | 9 | 2015 | 2919 | 0.660 |
Why?
| | Heart Transplantation | 7 | 2019 | 736 | 0.590 |
Why?
| | alpha 1-Antitrypsin Deficiency | 2 | 2018 | 59 | 0.560 |
Why?
| | Graft Rejection | 10 | 2019 | 540 | 0.560 |
Why?
| | Pneumonia, Viral | 1 | 2023 | 384 | 0.530 |
Why?
| | Pulmonary Medicine | 1 | 2017 | 79 | 0.500 |
Why?
| | Graft Survival | 6 | 2019 | 526 | 0.480 |
Why?
| | Lung | 11 | 2017 | 4109 | 0.470 |
Why?
| | Regeneration | 1 | 2017 | 197 | 0.460 |
Why?
| | Sirolimus | 3 | 2018 | 281 | 0.450 |
Why?
| | Diltiazem | 1 | 2014 | 17 | 0.420 |
Why?
| | Bronchial Arteries | 2 | 2010 | 12 | 0.410 |
Why?
| | RNA, Small Interfering | 2 | 2015 | 635 | 0.370 |
Why?
| | Transplant Recipients | 1 | 2014 | 180 | 0.360 |
Why?
| | Transplantation, Homologous | 11 | 2019 | 415 | 0.360 |
Why?
| | Organ Transplantation | 3 | 2018 | 247 | 0.350 |
Why?
| | Pulmonary Circulation | 2 | 2010 | 430 | 0.340 |
Why?
| | Polymorphism, Genetic | 1 | 2014 | 612 | 0.340 |
Why?
| | Virus Diseases | 2 | 2011 | 216 | 0.330 |
Why?
| | Patient Selection | 6 | 2015 | 719 | 0.320 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2012 | 202 | 0.320 |
Why?
| | Herpesviridae Infections | 1 | 2011 | 150 | 0.310 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2012 | 364 | 0.310 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2011 | 101 | 0.310 |
Why?
| | RNA Interference | 2 | 2013 | 476 | 0.310 |
Why?
| | Pulmonary Emphysema | 4 | 2015 | 275 | 0.300 |
Why?
| | Respiratory Tract Infections | 2 | 2011 | 397 | 0.280 |
Why?
| | Societies, Medical | 4 | 2018 | 887 | 0.280 |
Why?
| | Treatment Outcome | 10 | 2023 | 11679 | 0.270 |
Why?
| | Cytomegalovirus | 2 | 2004 | 168 | 0.250 |
Why?
| | Gene Expression Regulation | 3 | 2014 | 2608 | 0.240 |
Why?
| | Immunosuppressive Agents | 5 | 2019 | 846 | 0.230 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 5 | 2015 | 920 | 0.230 |
Why?
| | Humans | 42 | 2023 | 144759 | 0.220 |
Why?
| | Autoantibodies | 2 | 2013 | 1501 | 0.220 |
Why?
| | Vasculitis | 1 | 2005 | 69 | 0.220 |
Why?
| | Capillaries | 1 | 2005 | 124 | 0.210 |
Why?
| | Drug Resistance, Viral | 3 | 2011 | 122 | 0.210 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2004 | 126 | 0.200 |
Why?
| | Waiting Lists | 3 | 2015 | 263 | 0.200 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 2 | 2018 | 27 | 0.200 |
Why?
| | Reperfusion Injury | 3 | 2017 | 300 | 0.190 |
Why?
| | Heart-Lung Transplantation | 2 | 2014 | 13 | 0.190 |
Why?
| | Indazoles | 1 | 2023 | 80 | 0.190 |
Why?
| | Pneumonectomy | 2 | 2018 | 169 | 0.180 |
Why?
| | Risk Factors | 7 | 2013 | 10779 | 0.180 |
Why?
| | Evidence-Based Medicine | 1 | 2005 | 732 | 0.170 |
Why?
| | CD11b Antigen | 1 | 2019 | 60 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2019 | 72 | 0.150 |
Why?
| | Sulfonamides | 1 | 2023 | 580 | 0.140 |
Why?
| | Stem Cell Transplantation | 1 | 2019 | 191 | 0.140 |
Why?
| | Transplantation Tolerance | 1 | 2018 | 37 | 0.140 |
Why?
| | Primary Graft Dysfunction | 2 | 2017 | 35 | 0.130 |
Why?
| | Middle Aged | 15 | 2015 | 35875 | 0.130 |
Why?
| | Bronchoalveolar Lavage Fluid | 4 | 2020 | 636 | 0.130 |
Why?
| | Endothelial Cells | 2 | 2013 | 869 | 0.130 |
Why?
| | Transplantation, Heterotopic | 2 | 2014 | 16 | 0.130 |
Why?
| | Respiratory Function Tests | 2 | 2010 | 547 | 0.120 |
Why?
| | DNA, Mitochondrial | 1 | 2017 | 211 | 0.120 |
Why?
| | Syndrome | 3 | 2015 | 380 | 0.120 |
Why?
| | Immune Tolerance | 1 | 2018 | 379 | 0.120 |
Why?
| | Congresses as Topic | 1 | 2017 | 221 | 0.120 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2014 | 1129 | 0.120 |
Why?
| | Frailty | 1 | 2018 | 198 | 0.110 |
Why?
| | Adult | 10 | 2023 | 40449 | 0.110 |
Why?
| | International Cooperation | 1 | 2016 | 198 | 0.110 |
Why?
| | Interleukin-18 | 2 | 2013 | 235 | 0.110 |
Why?
| | Fas Ligand Protein | 1 | 2014 | 60 | 0.110 |
Why?
| | Male | 18 | 2015 | 72315 | 0.110 |
Why?
| | Tissue Donors | 2 | 2016 | 424 | 0.110 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2014 | 14 | 0.110 |
Why?
| | Asphyxia | 1 | 2014 | 23 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2014 | 5408 | 0.100 |
Why?
| | Receptors, Steroid | 1 | 2014 | 45 | 0.100 |
Why?
| | Female | 18 | 2019 | 78271 | 0.100 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2014 | 45 | 0.100 |
Why?
| | Tobacco Smoke Pollution | 2 | 2013 | 233 | 0.100 |
Why?
| | Everolimus | 1 | 2014 | 111 | 0.100 |
Why?
| | Anastomosis, Surgical | 2 | 2013 | 157 | 0.100 |
Why?
| | Health Resources | 1 | 2015 | 129 | 0.100 |
Why?
| | Tissue Distribution | 1 | 2014 | 327 | 0.100 |
Why?
| | Tissue and Organ Procurement | 2 | 2015 | 346 | 0.100 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2014 | 93 | 0.100 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2014 | 61 | 0.100 |
Why?
| | CD146 Antigen | 1 | 2013 | 40 | 0.100 |
Why?
| | Demography | 1 | 2014 | 288 | 0.100 |
Why?
| | Perfusion | 1 | 2014 | 250 | 0.100 |
Why?
| | Calcineurin Inhibitors | 2 | 2019 | 69 | 0.090 |
Why?
| | Immunocompromised Host | 2 | 2011 | 201 | 0.090 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2015 | 383 | 0.090 |
Why?
| | Animals | 13 | 2019 | 38058 | 0.090 |
Why?
| | Practice Guidelines as Topic | 2 | 2018 | 1560 | 0.090 |
Why?
| | Vasodilator Agents | 1 | 2014 | 331 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 917 | 0.090 |
Why?
| | Mice, Inbred BALB C | 4 | 2019 | 1253 | 0.090 |
Why?
| | Metabolic Clearance Rate | 1 | 2012 | 114 | 0.090 |
Why?
| | Predictive Value of Tests | 3 | 2013 | 2115 | 0.090 |
Why?
| | Injections, Intravenous | 1 | 2012 | 200 | 0.090 |
Why?
| | Seroepidemiologic Studies | 1 | 2012 | 172 | 0.090 |
Why?
| | Liver Transplantation | 1 | 2018 | 823 | 0.090 |
Why?
| | Cytokines | 2 | 2010 | 2061 | 0.080 |
Why?
| | Viral Vaccines | 1 | 2011 | 107 | 0.080 |
Why?
| | Neprilysin | 1 | 2010 | 47 | 0.080 |
Why?
| | Polymerase Chain Reaction | 2 | 2004 | 1054 | 0.080 |
Why?
| | Airway Remodeling | 1 | 2010 | 64 | 0.080 |
Why?
| | Cell Communication | 1 | 2012 | 324 | 0.080 |
Why?
| | Double-Blind Method | 2 | 2015 | 2029 | 0.080 |
Why?
| | Gene Expression | 1 | 2014 | 1490 | 0.080 |
Why?
| | CD4 Antigens | 1 | 2010 | 139 | 0.070 |
Why?
| | Adoptive Transfer | 1 | 2010 | 198 | 0.070 |
Why?
| | Cross-Over Studies | 1 | 2012 | 601 | 0.070 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2010 | 177 | 0.070 |
Why?
| | Preoperative Care | 1 | 2012 | 379 | 0.070 |
Why?
| | Genotype | 1 | 2014 | 1833 | 0.070 |
Why?
| | Administration, Inhalation | 1 | 2010 | 574 | 0.070 |
Why?
| | Respiration, Artificial | 1 | 2014 | 708 | 0.070 |
Why?
| | Cost of Illness | 1 | 2011 | 321 | 0.070 |
Why?
| | Length of Stay | 1 | 2015 | 1337 | 0.070 |
Why?
| | Pulmonary Artery | 2 | 2012 | 1134 | 0.070 |
Why?
| | Blood Specimen Collection | 1 | 2008 | 38 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 983 | 0.070 |
Why?
| | Bacteriological Techniques | 1 | 2008 | 68 | 0.070 |
Why?
| | Regional Blood Flow | 1 | 2010 | 514 | 0.070 |
Why?
| | Pulmonary Fibrosis | 2 | 2013 | 395 | 0.070 |
Why?
| | C-Reactive Protein | 1 | 2010 | 416 | 0.070 |
Why?
| | Macrophages, Alveolar | 2 | 2013 | 368 | 0.070 |
Why?
| | Referral and Consultation | 1 | 2014 | 851 | 0.070 |
Why?
| | Biomarkers | 3 | 2014 | 4271 | 0.070 |
Why?
| | Cyclosporine | 2 | 2019 | 265 | 0.070 |
Why?
| | Recurrence | 1 | 2011 | 1135 | 0.070 |
Why?
| | Body Temperature | 1 | 2008 | 229 | 0.070 |
Why?
| | Macrophages | 2 | 2013 | 1511 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2027 | 0.070 |
Why?
| | Fever | 1 | 2008 | 311 | 0.060 |
Why?
| | Trachea | 2 | 2007 | 261 | 0.060 |
Why?
| | Mice | 9 | 2019 | 18339 | 0.060 |
Why?
| | Nurse Practitioners | 1 | 2008 | 140 | 0.060 |
Why?
| | Time Factors | 5 | 2015 | 7173 | 0.060 |
Why?
| | Bacteremia | 1 | 2008 | 221 | 0.060 |
Why?
| | Terminology as Topic | 1 | 2007 | 255 | 0.060 |
Why?
| | Cryptogenic Organizing Pneumonia | 1 | 2005 | 19 | 0.060 |
Why?
| | Tissue Transplantation | 1 | 2005 | 9 | 0.060 |
Why?
| | Mice, Inbred C57BL | 4 | 2019 | 5992 | 0.060 |
Why?
| | Prognosis | 1 | 2014 | 4282 | 0.060 |
Why?
| | CD40 Ligand | 1 | 2005 | 40 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1356 | 0.050 |
Why?
| | Survival | 1 | 2004 | 38 | 0.050 |
Why?
| | Antibodies, Monoclonal | 2 | 2018 | 1519 | 0.050 |
Why?
| | Mice, Inbred C3H | 2 | 2018 | 251 | 0.050 |
Why?
| | Rats | 4 | 2013 | 5597 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2004 | 160 | 0.050 |
Why?
| | Drug Resistance | 1 | 2004 | 153 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2012 | 1982 | 0.050 |
Why?
| | Aged | 7 | 2014 | 25913 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2005 | 779 | 0.050 |
Why?
| | Quality Assurance, Health Care | 1 | 2005 | 340 | 0.050 |
Why?
| | Torsion Abnormality | 1 | 2003 | 20 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 3 | 2013 | 2527 | 0.050 |
Why?
| | Capillary Permeability | 2 | 2013 | 134 | 0.050 |
Why?
| | Registries | 1 | 2012 | 2385 | 0.050 |
Why?
| | Fibrosis | 1 | 2005 | 548 | 0.050 |
Why?
| | Hypoxia | 1 | 2010 | 1199 | 0.050 |
Why?
| | Cross-Sectional Studies | 1 | 2014 | 5868 | 0.050 |
Why?
| | Respiratory Mucosa | 1 | 2005 | 322 | 0.050 |
Why?
| | Incidence | 1 | 2009 | 2879 | 0.040 |
Why?
| | Prevalence | 1 | 2009 | 2834 | 0.040 |
Why?
| | Mice, Transgenic | 2 | 2018 | 2182 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2007 | 965 | 0.040 |
Why?
| | Genomics | 1 | 2006 | 834 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2013 | 85 | 0.040 |
Why?
| | Transplantation Immunology | 2 | 2013 | 29 | 0.040 |
Why?
| | Polyphosphates | 1 | 2020 | 45 | 0.040 |
Why?
| | Neutrophils | 1 | 2006 | 1134 | 0.040 |
Why?
| | Ribavirin | 1 | 2020 | 80 | 0.040 |
Why?
| | Cell Line | 3 | 2013 | 2882 | 0.040 |
Why?
| | Young Adult | 3 | 2014 | 14105 | 0.040 |
Why?
| | Early Diagnosis | 2 | 2013 | 249 | 0.040 |
Why?
| | Abatacept | 1 | 2019 | 56 | 0.040 |
Why?
| | Mice, Knockout | 3 | 2013 | 3121 | 0.040 |
Why?
| | Case-Control Studies | 3 | 2013 | 3604 | 0.040 |
Why?
| | Prospective Studies | 1 | 2012 | 7990 | 0.040 |
Why?
| | Mice, Inbred Strains | 2 | 2013 | 397 | 0.040 |
Why?
| | Allografts | 1 | 2019 | 150 | 0.040 |
Why?
| | Adolescent | 4 | 2014 | 22428 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2019 | 148 | 0.040 |
Why?
| | CD28 Antigens | 1 | 2018 | 58 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2013 | 1716 | 0.030 |
Why?
| | Health Care Rationing | 1 | 2018 | 59 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2004 | 1782 | 0.030 |
Why?
| | Sensitivity and Specificity | 3 | 2008 | 1985 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2015 | 17066 | 0.030 |
Why?
| | Cardiomyopathies | 1 | 2019 | 338 | 0.030 |
Why?
| | Isoantibodies | 1 | 2016 | 57 | 0.030 |
Why?
| | Acute Disease | 2 | 2010 | 1030 | 0.030 |
Why?
| | Stem Cells | 1 | 2019 | 626 | 0.030 |
Why?
| | Genes, RAG-1 | 1 | 2014 | 12 | 0.030 |
Why?
| | DNA Repair | 1 | 2017 | 256 | 0.030 |
Why?
| | Cell Movement | 2 | 2012 | 965 | 0.030 |
Why?
| | DNA Damage | 1 | 2017 | 430 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2017 | 621 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2018 | 1126 | 0.030 |
Why?
| | Tidal Volume | 1 | 2014 | 111 | 0.020 |
Why?
| | Chemokine CCL5 | 1 | 2013 | 41 | 0.020 |
Why?
| | Positive-Pressure Respiration | 1 | 2014 | 112 | 0.020 |
Why?
| | Gene Deletion | 1 | 2014 | 389 | 0.020 |
Why?
| | Pulmonary Edema | 1 | 2013 | 106 | 0.020 |
Why?
| | Aorta, Abdominal | 1 | 2013 | 52 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 74 | 0.020 |
Why?
| | Patient Admission | 1 | 2015 | 218 | 0.020 |
Why?
| | Neck | 1 | 2013 | 108 | 0.020 |
Why?
| | Inhalation Exposure | 1 | 2013 | 115 | 0.020 |
Why?
| | Rats, Nude | 1 | 2012 | 25 | 0.020 |
Why?
| | Immunity, Innate | 1 | 2018 | 846 | 0.020 |
Why?
| | Tobacco Products | 1 | 2013 | 84 | 0.020 |
Why?
| | Fluoresceins | 1 | 2012 | 48 | 0.020 |
Why?
| | History, 21st Century | 1 | 2013 | 219 | 0.020 |
Why?
| | Abdomen | 1 | 2013 | 141 | 0.020 |
Why?
| | Cardiomegaly | 1 | 2013 | 174 | 0.020 |
Why?
| | History, 20th Century | 1 | 2013 | 325 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2013 | 381 | 0.020 |
Why?
| | Cell Death | 1 | 2013 | 383 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2012 | 197 | 0.020 |
Why?
| | Child | 1 | 2011 | 22633 | 0.020 |
Why?
| | Transfection | 1 | 2013 | 940 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2013 | 557 | 0.020 |
Why?
| | Aorta, Thoracic | 1 | 2013 | 286 | 0.020 |
Why?
| | Survival Rate | 1 | 2015 | 2089 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2012 | 329 | 0.020 |
Why?
| | Myocytes, Cardiac | 1 | 2014 | 556 | 0.020 |
Why?
| | H-2 Antigens | 1 | 2010 | 111 | 0.020 |
Why?
| | Myocardium | 1 | 2014 | 939 | 0.020 |
Why?
| | Oximetry | 1 | 2010 | 126 | 0.020 |
Why?
| | United States | 2 | 2018 | 15966 | 0.020 |
Why?
| | Bronchoscopy | 1 | 2010 | 227 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2008 | 121 | 0.020 |
Why?
| | Patient Discharge | 1 | 2015 | 983 | 0.020 |
Why?
| | International Agencies | 1 | 2007 | 30 | 0.020 |
Why?
| | Receptors, Interleukin-8B | 1 | 2007 | 23 | 0.020 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2008 | 96 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1187 | 0.020 |
Why?
| | Pulmonary Alveoli | 1 | 2010 | 383 | 0.020 |
Why?
| | Weight Loss | 1 | 2013 | 836 | 0.020 |
Why?
| | Decompression, Surgical | 1 | 2008 | 116 | 0.020 |
Why?
| | Microcirculation | 1 | 2007 | 138 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2007 | 183 | 0.020 |
Why?
| | Cell Survival | 1 | 2010 | 1098 | 0.020 |
Why?
| | Suicide | 1 | 2014 | 720 | 0.020 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2006 | 113 | 0.010 |
Why?
| | Evidence-Based Practice | 1 | 2008 | 238 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2013 | 4154 | 0.010 |
Why?
| | Transplantation Chimera | 1 | 2005 | 56 | 0.010 |
Why?
| | Reoperation | 1 | 2008 | 630 | 0.010 |
Why?
| | Eosinophilia | 1 | 2007 | 221 | 0.010 |
Why?
| | Oxygen | 1 | 2010 | 995 | 0.010 |
Why?
| | Ischemia | 1 | 2007 | 421 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2012 | 2496 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 758 | 0.010 |
Why?
| | Models, Biological | 1 | 2012 | 1821 | 0.010 |
Why?
| | Biopsy | 1 | 2007 | 1075 | 0.010 |
Why?
| | Inpatients | 1 | 2008 | 545 | 0.010 |
Why?
| | Respiratory System | 1 | 2005 | 149 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1489 | 0.010 |
Why?
| | Kinetics | 1 | 2006 | 1627 | 0.010 |
Why?
| | Respirovirus | 1 | 2002 | 6 | 0.010 |
Why?
| | Virus Cultivation | 1 | 2002 | 31 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4557 | 0.010 |
Why?
| | Influenza B virus | 1 | 2002 | 47 | 0.010 |
Why?
| | Immunoenzyme Techniques | 1 | 2002 | 200 | 0.010 |
Why?
| | Pneumonia | 1 | 2007 | 631 | 0.010 |
Why?
| | Influenza A virus | 1 | 2002 | 113 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2014 | 6048 | 0.010 |
Why?
| | Chronic Disease | 1 | 2007 | 1813 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2008 | 3409 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 1980 | 0.010 |
Why?
| | Immunotherapy | 1 | 2005 | 653 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2010 | 2730 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2004 | 1496 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2004 | 2832 | 0.010 |
Why?
| | Inflammation | 1 | 2005 | 2878 | 0.010 |
Why?
|
|
Zamora's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|